EBS FY 2014 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$430M

FY 2014 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$404M+29.3% YoY

Gross Profit

$198M48.9% margin

Operating Income

$89M22.1% margin

Net Income

$37M9.1% margin

EPS (Diluted)

$0.88

Cash Flow

Operating Cash Flow

$112M

Free Cash Flow

$82M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$945M

Total Liabilities

$392M

Stockholders' Equity

$553M

Cash & Equivalents

$280M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$404M	$313M	+29.3%
Gross Profit	$198M	$131M	+51.3%
Operating Income	$89M	$43M	+108.4%
Net Income	$37M	$31M	+18.0%